strong quarter beat/rais outlin
provid initi outlook double-digit
earn growth despit increas project
ou humira eros
new ou humira
market lock price
optimist venclexta approv aml ye
add new acceler product
contract season humira posit
similar outlook
calquenc market share mcl peak
actual declin suggest drug
differenti despit price azn paid get
model revis pt
modest adjust spend estim
readjust account sbc model
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
expand studi add sickl
patient explor correl hb
paramet patient event -- -basic
obviou analysiswhich help inform next
pivot read faster sinc wont need
reli event-driven endpoint mayb stretch
think file studi unclear
type follow-up need drive
correl event driven compar
patient prior experi patient
events/yr may take month confid
trajectori chang like
may events/yr case might
valuat deriv pt use dcf
discount rate termin
growth rate discount rate standard rate appli
across derisk biopharma compani reflect
believ appropri return sharehold
termin growth rate reflect durabl natur
compani biolog franchis
risk clearli humira domin product model still
assum repres total model revenu
framework biosimilar adopt chang
humira method use patent fall multipl biosimilar
launch simultan creat pent-up precipit
impact sale share could suffer
valuat deriv pt use dcf
discount rate termin
risk face develop regulatori
commercial/competit risk gene therapi car-t
track rel beat/miss
commentari around product serial around quarter includ
half growth driven
volum
ra spa
psoriasi crohn
humira medicar
impact retail inventori
destock larg specialti
shipment time
across approv
modest stock benefit
launch new
ou eros
moder
market share gain across
line therapi cll
report roch
pt start
close
cover live
mavyret sale
failur patient japan
mavyret market lead
posit us strong
leadership posit
number ex-u market
mavryet
intern result
benefit time
serial guidanc updat
peak
mid-single-digit prior
hcv sale
note fy
note fy
note fy guidanc
global hcv
ou market creon
note fy
increas
y/i
y/i
y/i midpoint
y/i
addit commentari key programs/pipelin
pdufa endometriosi
announc
approv juli endometriosi launch
present uterin fibroid data asrm
regulatori submiss uterin fibroid
approv juli endometriosi
present uterin fibroid data
asrm regulatori submiss
uterin fibroid
launch on-going build awar
broad coverag start jan averag
present uterin fibroid data aagl
submit snda
data cll w/ gazyva
dlbcl w/ r-chop data
shine mcl perspect fl
selen r/r fl mzl
present illumin
capitiv data work
addit cll data next year
sever on-going studi imbruvica
wide use compar young
fit patient fcr br gazyva
chlorambucil watch wait patient
gazyva allianc imb mono
combo vs br data expand
cll studi young fit watch
wait patient on-going data young fit
patient expect
cll studi young fit
watch wait patient on-going
data
snda submiss r/r cll complet
expect approv
data aml mm submit
snda aml potenti
initi pivot mm
cll data
cll studi cll launch
present upcom confer
submit snda aml receiv
induct therapi jul data aml
possibl data mm target subset
fairli substanti patient
good fit inhibitor
aml receiv induct therapi
aml market pdufa dec
confirmatori result
bellini mm studi start
pivot mm mcl
bellini mm studi initi
studi mm
eular june
submit nda commerci
expect
start ad uc giant cell arter
report full ad aad
on-going psoriat arthriti cd
also evalu
submit bla psoriasi
start cd expect begin studi
uc
start cd ad
present uc data ueg
present addit data ra acr
begin gca on-going
submit bla ema applic submit
submit bla bla accept
start cd
on-going studi cd on-going uc
expect initi
jak/btk combo began ra
begin lupu
antagonist transit uc
anti-tnf steroid
begin
triniti sclc top-line data
present data asco
triniti data present file
acceler approv sclc
data combo i/o data
possibl data combo i/o data
meru taho data expect
meru mainten sclc late
possibl addit data
neuroendocrin basket studi
colorect cancer
ovarian cancer data
colorect cancer
ovarian cancer data
data later
vela data non-squam nsclc
vela data non-squam nsclc
proceed second tripl combo
glpg review futur cf collabor
esrx npf launch author
gbm data
vela data non-squam nsclc mid
take cf program up-front
royalti glpg
articl articl
time dissemin novemb
analyst josh schimmer shenston huang ami liu maneka mirchandaney primarili respons prepar research
report attest follow view opinion render research report reflect person view subject
compani issuer part research analyst compens directli relat specif
recommend view research report
